Fjarde AP Fonden Fourth Swedish National Pension Fund Has $7.93 Million Holdings in IQVIA Holdings Inc. $IQV

Fjarde AP Fonden Fourth Swedish National Pension Fund increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 80.6% during the first quarter, Holdings Channel.com reports. The fund owned 46,506 shares of the medical research company’s stock after purchasing an additional 20,750 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in IQVIA were worth $7,931,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of IQVIA by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after purchasing an additional 159,899 shares during the period. Geode Capital Management LLC grew its position in IQVIA by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock worth $982,272,000 after buying an additional 24,453 shares in the last quarter. Boston Partners increased its stake in IQVIA by 14.9% during the 4th quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock worth $923,276,000 after acquiring an additional 530,672 shares during the period. JPMorgan Chase & Co. raised its holdings in IQVIA by 16.2% in the 4th quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock valued at $856,468,000 after acquiring an additional 528,753 shares in the last quarter. Finally, Alliancebernstein L.P. lifted its position in shares of IQVIA by 1.2% during the 3rd quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock valued at $683,323,000 after acquiring an additional 41,643 shares during the period. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on IQV. HSBC set a $210.00 price target on IQVIA in a research report on Wednesday, June 3rd. Morgan Stanley reiterated an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Robert W. Baird raised their target price on shares of IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a report on Wednesday, July 1st. Evercore restated an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research report on Wednesday, April 8th. Finally, TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and increased their price target for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $222.00.

IQVIA Trading Down 0.3%

IQV opened at $206.38 on Monday. The company’s 50 day moving average is $176.95 and its 200-day moving average is $189.05. The company has a market cap of $34.44 billion, a P/E ratio of 25.57, a PEG ratio of 1.78 and a beta of 1.20. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $247.04. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company’s quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the business posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its board has initiated a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.